Compass Pathways is a biotechnology company developing evidence-based psilocybin-based treatments for serious mental health conditions, with its lead candidate being COMP360, a proprietary pharmaceutical-grade psilocybin formulation designed to deliver rapid and sustained therapeutic response. The company primarily focuses on treatment-resistant depression, a condition affecting millions of patients annually for whom existing therapies have proven inadequate, while also pursuing development in post-traumatic stress disorder and other central nervous system conditions. Compass retains global development and commercialization rights to COMP360 and plans to generate revenue through direct-to-provider sales and marketing in the United States following regulatory approval, complemented by commercialization partnerships in select international markets and collaborations with healthcare delivery systems to implement treatment protocols.